English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2566486      線上人數 : 279
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    主頁登入上傳說明關於NHRI管理 到手機版
    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12655


    題名: Combination therapy of pulsed-wave ultrasound hyperthermia and immunostimulant OK-432 enhances systemic antitumor immunity for cancer treatment
    作者: Li, TC;Liu, CC;Lee, YZ;Hsu, YH;Chiang, CF;Miaw, SC;Lin, WL
    貢獻者: Institute of Biomedical Engineering and Nanomedicine
    摘要: PURPOSE: In this study, we hypothesized that systemic antitumor immunity might be enhanced by combining pulsed-wave ultrasound hyperthermia (pUSHT) with OK-432 and that the induced antitumor immunity could confer protection against tumorigenesis. These hypotheses were tested in bilateral and rechallenged tumor models. MATERIALS AND METHODS: Bilateral and rechallenged tumor models were applied in the studies. In the bilateral tumor model, BALB/c mice were inoculated with CT26-luc tumor cells into both flanks. The tumors in the right flank were treated with four courses of pUSHT with or without OK-432. In the rechallenged tumor model, tumor cells were implanted into the right flank. Once formed, the tumors were treated with pUSHT with OK-432, followed by surgical resection. New tumor cells were then implanted into the contralateral flank. The antitumor response was evaluated by infiltrated immune cells and the severity of necrosis/apoptosis in tumors. RESULTS: In the bilateral tumor model, the tumor growth rate and growth activity of both treated (100% reduction) and untreated tumors (90.5% reduction) were significantly inhibited with the combination treatment compared with the sham control group, and the systemic anti-tumor effect was prolonged. The survival rate was significantly enhanced (sham control: 8 days; OK+pUSHT: >20 days). IFNgamma(+) CD4 (treated tumor: 8.6-fold; untreated tumor: 4-fold), IFNgamma(+) CD8 (treated tumor: 6.7-fold; untreated tumor: 2.6-fold) T-cell and NK-cell (treated tumor: 4-fold; untreated tumor: 2.5-fold) infiltration were increased in the combination group compared with the control group. In the rechallenged tumor model, new tumors failed to form for the combination treatment. CONCLUSION: This experimental study combining pUSHT and OK-432 explored a new therapeutic strategy for controlling colon cancer metastasis, and the results showed that the combination treatment may produce an effective anti-tumor immune response.
    日期: 2020-09-01
    關聯: International Journal of Radiation Oncology, Biology, Physics. 2020 Sep 1;108(1):140-149.
    Link to: http://dx.doi.org/10.1016/j.ijrobp.2020.04.021
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0360-3016&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000561895300016
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85087070677
    顯示於類別:[其他] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB32339644.pdf13583KbAdobe PDF313檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋